Clinical Trial Update: Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating acalabrutinib in combination with durvalumab for patients with central nervous system lymphoma (primary and secondary).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Acalabrutinib (acalabrutinib)
• Durvalumab (durvalumab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Primary Central Nervous System Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING